SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease.

Seock-Ah  Im

Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; GlaxoSmithKline; Hanmi; Lilly; MSD; Novartis; Pfizer; Roche/Genentech

Research Funding - AstraZeneca (Inst); Daewoong Pharmaceutical (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)

Other Relationship - Roche

Erika P.  Hamilton

Consulting or Advisory Role - Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Deciphera (Inst); Eisai (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Seagen (Inst); Silverback Therapeutics (Inst)

Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Akeso Biopharma (Inst); Amgen (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Orinove (Inst); Pfizer (Inst); PharmaMar (Inst); Plexxikon (Inst); Polyphor (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Torque (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)

Antonio  Llombart Cussac

No Relationships to Disclose

Richard D.  Baird

Honoraria - Molecular Partners (Inst)

Consulting or Advisory Role - AstraZeneca (Inst); Daiichi Sankyo (Inst); Molecular Partners (Inst); Novartis (Inst); Roche/Genentech (Inst); Shionogi (Inst)

Research Funding - AstraZeneca (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Carrick Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Molecular Partners (Inst); Roche (Inst); Sanofi (Inst); Shionogi (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Molecular Partners; Shionogi

Johannes  Ettl

Honoraria - AstraZeneca; Celgene; Lilly; Novartis; Pfizer; Pierre Fabre; Roche; Tesaro; Teva

Consulting or Advisory Role - Daiichi Sankyo; Lilly; Novartis; Pfizer; Pierre Fabre; Roche; Tesaro

Speakers' Bureau - AstraZeneca; Celgene; Lilly; Pfizer; Roche; Teva

Research Funding - Lilly (Inst)

Travel, Accommodations, Expenses - Celgene; Lilly; Novartis; Pfizer; Teva

Other Relationship - Tesaro

Matthew P.  Goetz

Consulting or Advisory Role - bioTheranostics; Biovica; Context Therapeutics; Eisai; Genomic Health; Lilly; Novartis; Pfizer; Sermonix Pharmaceuticals

Research Funding - Lilly (Inst); Pfizer (Inst); Sermonix Pharmaceuticals (Inst)

Patents, Royalties, Other Intellectual Property - Development of Human Tumor Xenografts from Women with Breast Cancer Treated with Neoadjuvant Chemotherapy (Inst); Methods and Materials for Assessing Chemotherapy Responsiveness and Treating Cancer; METHODS AND MATERIALS FOR USING BUTYRYLCHOLINESTERASES TO TREAT CANCER

Travel, Accommodations, Expenses - Lilly

Hiroji  Iwata

Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; Pfizer; Taiho Pharmaceutical

Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Novartis; Pfizer

Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)

Anil Abraham  Joy

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Exactis Innovation; Lilly; Novartis; Pfizer; Roche; Teva

Travel, Accommodations, Expenses - Roche

Patrick  Neven

Consulting or Advisory Role - Lilly (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Radius Health (Inst); Roche (Inst); Roche (Inst)

Travel, Accommodations, Expenses - Lilly (Inst); Pfizer (Inst); Roche (Inst)

Vincent  Haddad

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Andrew Stephen  Walding

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Travel, Accommodations, Expenses - AstraZeneca

Manuel  Selvi Miralles

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Honoraria - AstraZeneca

Travel, Accommodations, Expenses - AstraZeneca

Cynthia Huang  Bartlett

Employment - AstraZeneca; Merck; Pfizer

Stock and Other Ownership Interests  - AstraZeneca; Pfizer

Fabrice  Andre

Stock and Other Ownership Interests  - PEGASCY

Research Funding - AstraZeneca (Inst); Daiichi (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)

Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Novartis; Roche